{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:09Z","timestamp":1786119369034,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tumour treating fields (TTFields) have demonstrated efficacy in extending survival in the temozolomide maintenance therapy phase. Consequently, the purpose of this study is to investigate the safety and efficacy of TTFields in combination with concurrent chemoradiotherapy for newly diagnosed glioblastoma (GBM) patients, as well as analyzing the prognostic factors for these patients, can provide valuable data to guide the clinical application of TTFields.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study retrospectively analyzed the clinical treatment of 68 GBM patients receiving the TTFields, admitted to the Department of Radiation Oncology at Jiangsu Cancer Hospital from September 2021 to October 2024. Progression-free survival (PFS) curves and overall survival were constructed using the Kaplan\u2013Meier method. A Cox proportional hazards regression model was used to assess the effect of TTFields and to account for confounding factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 68 GBM patients included in the study, the median PFS was 16.4 months (95% CI: 13.3\u201319.5), the median overall survival was 28.8 months (95% CI: 20.6\u201337.0) for all 68 patients. The objective response rate was 64.7% (44\/68), and the disease control rate was 94.1% (64\/68). Multivariate analysis revealed that surgery type and compliance rate with TTFs were favorable prognostic factors. Mild to moderate skin toxicity underneath the transducer arrays occurred in 51.4% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In our final analysis of single-center Chinese patients with newly diagnosed GBM, concurrent chemoradiotherapy with TTFields resulted in promising PFS outcomes that warrant validation in propensity-matched or randomized studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048383","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:02:49Z","timestamp":1777273369000},"page":"e48383","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tumor-treating fields combined with concurrent chemoradiotherapy for newly diagnosed glioblastoma patients"],"prefix":"10.1097","volume":"105","author":[{"given":"Zixuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Postgraduate College, NanJing Medical University, Nanjing, China"},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Postgraduate College, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanfeng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Nantong University, Nantong First People\u2019s Hospital, Medical School of Nantong University, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Postgraduate College, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Yu","sequence":"additional","affiliation":[{"name":"Postgraduate College, NanJing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-1002","authenticated-orcid":false,"given":"Xia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Postgraduate College, NanJing Medical University, Nanjing, China"},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Nanjing, China"},{"name":"Postgraduate College, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","first-page":"165","article-title":"Analysis of age characteristics of malignant tumour incidence and death in the Chinese population in 2022.","volume":"33","author":"Shaoming","year":"2024","journal-title":"China Cancer"},{"issue":"Suppl 4","key":"R2-20260622","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro-Oncology"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-20260622","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.3390\/cancers14153669","article-title":"Tumor-treating fields in glioblastomas: past, present, and future.","volume":"14","author":"Guo","year":"2022","journal-title":"Cancers"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomised clinical trial.","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/cco-22-90","article-title":"Tumor treating fields with radiation for glioblastoma: a narrative review.","volume":"11","author":"Miller","year":"2022","journal-title":"Chin Clin Oncol"},{"key":"R7-20260622","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6649-9-1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields).","volume":"9","author":"Kirson","year":"2009","journal-title":"BMC Med Phys"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1259\/bjr\/83827377","article-title":"Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?","volume":"85","author":"Hingorani","year":"2012","journal-title":"Br J Radiol"},{"key":"R10-20260622","first-page":"CD008218","article-title":"Anti-angiogenic therapy for high-grade glioma.","volume":"11","author":"Ameratunga","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000137713","article-title":"A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and\/or metastatic solid tumours.","volume":"31","author":"Salzberg","year":"2008","journal-title":"Onkologie"},{"key":"R12-20260622","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumour models and human brain tumors.","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc Nat Acad Sci USA"},{"key":"R13-20260622","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13014-020-01521-7","article-title":"Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.","volume":"15","author":"Guberina","year":"2020","journal-title":"Radiation Oncol (London, England)"},{"issue":"Suppl 6","key":"R15-20260622","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2014.09.010","article-title":"Clinical practice experience with NovoTTF-100A\u2122 system for glioblastoma: the patient registry dataset (PRiDe).","volume":"41","author":"Mrugala","year":"2014","journal-title":"Semin Oncol"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1634\/theoncologist.2019-0838","article-title":"The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303).","volume":"25","author":"Jiang","year":"2020","journal-title":"Oncologist"},{"key":"R17-20260622","doi-asserted-by":"crossref","first-page":"896246","DOI":"10.3389\/fonc.2022.896246","article-title":"Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.","volume":"12","author":"Miller","year":"2022","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:09Z","timestamp":1786039689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":17,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048383","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2024-12-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}